Metabolic characterization of the R6/2 transgenic mouse model of Huntington's disease by high-resolution MAS 1H NMR spectroscopy

Journal of Proteome Research

Volumn 5, Issue 3, 2006, Pages 483-492

  Tsang, Tsz M ^a   Woodman, Ben ^b   Mcloughlin, Gerard A ^a   Griffin, Julian L ^a,c   Tabrizi, Sarah J ^d   Bates, Gillian P ^b   Holmes, Elaine ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Huntington's disease; Metabolic profiling; NMR spectroscopy; Pattern recognition; R6 2 mice

Indexed keywords

4 AMINOBUTYRIC ACID; ACETIC ACID; CHOLINE; CREATINE; GLUTAMINE; LACTIC ACID; N ACETYLASPARTIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; BRAIN REGION; CONTROLLED STUDY; HUNTINGTON CHOREA; MALE; MOUSE; MUSCLE; NEWBORN; NONHUMAN; PATTERN RECOGNITION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TRANSGENIC MOUSE; URINE;

ANIMALS; BIOLOGICAL MARKERS; BRAIN CHEMISTRY; DISEASE MODELS, ANIMAL; FEMALE; HUNTINGTON DISEASE; LONGITUDINAL STUDIES; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, TRANSGENIC; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR;

ANIMALIA; MUS MUSCULUS;

EID: 33644843611     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr050244o     Document Type: Article

References (71)

1. Huntington's Disease, 3rd ed.; Bates, G. P., Harper, P. S., Jones, A. L., Eds.; Oxford University Press: Oxford, 2002.
2. Rubinsztein, D. C.; Leggo, J.; Coles, R.; Almqvist, E.; Biancalana, V.; Cassiman, J. J. et al. Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am. J. Hum. Genet. 1996, 59, 16-22.
3. Bates, G. Huntingtin aggregation and toxicity in Huntington's disease. Lancet 2003, 361, 1642-1644.
4. Luthi-Carter, R.; Cha, J.-H. J. Mechanisms of transcriptional dysregulation in Huntington's disease. Clin. Neurosci. Res. 2003, 3, 165-177.
5. Landles, C.; Bates, G. P. Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO Rep. 2004, 5, 958-963.
6. Browne, S. E.; Beal, M. F. The energetics of Huntington's disease. Neurochem. Res. 2004, 29, 531-546.
7. Bezprozvanny, I.; Hayden, M. R. Deranged neuronal calcium signaling and Huntington disease. Biochem. Biophys. Res. Commun. 2004, 322, 1310-1317.
8. Gunawardena, S.; Goldstein, L. S. Polyglutamine diseases and transport problems: deadly traffic jams on neuronal highways. Arch. Neurol. 2005, 62, 46-51.
9. Wilson, I. D.; Plumb, R.; Granger, J.; Major, H.; Williams, R.; Lenz, E. M. HPLC-MS-based methods for the study of metabonomics. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005, 817, 67-76.
10. Nicholson, J. K.; Connelly, J.; Lindon, J. C.; Holmes, E. Metabonomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov. 2002, 1, 153-161.
11. Lindon, J. C.; Holmes, E.; Bollard, M. E.; Stanley, E. G.; Nicholson, J. K. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers 2004, 9, 1-31.
12. Brindle, J. T.; Antti, H.; Holmes, E.; Tranter, G.; Nicholson, J. K.; Bethell, H. W. et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H NMR-based metabonomics. Nat. Med. 2002, 8, 1439-1444.
13. Moolenaar, S. H.; Gohlich-Ratmann, G.; Engelke, U. F.; Spraul, M.; Humpfer, E.; Dvortsak, P. et al. beta-Ureidopropionase deficiency: a novel inborn error of metabolism discovered using NMR spectroscopy on urine. Magn. Reson. Med. 2001, 46, 1014-1017.
14. Griffin, J. L.; Williams, H. J.; Sang, E.; Nicholson, J. K. Abnormal lipid profile of dystrophic cardiac tissue as demonstrated by one-and two-dimensional magic-angle spinning (1)H NMR spectroscopy. Magn. Reson. Med. 2001, 46, 249-255.
15. Gavaghan, C. L.; Holmes, E.; Lenz, E.; Wilson, I. D.; Nicholson, J. K. An NMR-based metabonomic approach to investigate the biochemical consequences of genetic strain differences: application to the C57BL10J and Alpk: ApfCD mouse. FEBS Lett. 2000, 484, 169-174.
16. Cheng, L. L.; Lean, C. L.; Bogdanova, A.; Wright, S. C., Jr.; Ackerman, J. L.; Brady, T. J. et al. Enhanced resolution of proton NMR spectra of malignant lymph nodes using magic-angle spinning. Magn. Reson. Med. 1996, 36, 653-658.
17. Millis, K. K.; Maas, W. E.; Cory, D. G.; Singer, S. Gradient, high-resolution, magic-angle spinning nuclear magnetic resonance spectroscopy of human adipocyte tissue. Magn. Reson. Med. 1997, 38, 399-403.
18. Waters, N. J.; Garrod, S.; Farrant, R. D.; Haselden, J. N.; Connor, S. C.; Connelly, J. et al. High-resolution magic angle spinning (1)H NMR spectroscopy of intact liver and kidney: optimization of sample preparation procedures and biochemical stability of tissue during spectral acquisition. Anal. Biochem. 2000, 282, 16-23.
19. Garrod, S.; Humpher, E.; Connor, S. C.; Connelly, J. C.; Spraul, M.; Nicholson, J. K. et al. High-resolution (1)H NMR and magic angle spinning NMR spectroscopic investigation of the biochemical effects of 2-bromoethanamine in intact renal and hepatic tissue. Magn. Reson. Med. 2001, 45, 781-790.
20. Waters, N. J.; Holmes, E.; Williams, A.; Waterfield, C. J.; Farrant, R. D.; Nicholson, J. K. NMR and pattern recognition studies on the time-related metabolic effects of alpha-naphthylisothiocyanate on liver, urine, and plasma in the rat: an integrative metabonomic approach. Chem. Res. Toxicol. 2001, 14, 1401-1412.
21. Bollard, M. E.; Xu, J.; Purcell, W.; Griffin, J. L.; Quirk, C.; Holmes, E. et al. Metabolic profiling of the effects of D-galactosamine in liver spheroids using (1)H NMR and MAS NMR spectroscopy. Chem. Res. Toxicol. 2002, 15, 1351-1359.
22. Griffin, J. L.; Bollard, M.; Nicholson, J. K.; Bhakoo, K. Spectral profiles of cultured neuronal and glial cells derived from HRMAS (1)H NMR spectroscopy. NMR Biomed. 2002, 15, 375-384.
23. Tsang, T. M.; Griffin, J. L.; Haselden, J.; Fish, C.; Holmes, E. Metabolic characterization of distinct neuroanatomical regions in rats by magic angle spinning H-1 nuclear magnetic resonance spectroscopy. Magn. Reson. Med. 2005, 53, 1018-1024.
24. Mangiarini, L.; Sathasivam, K.; Seller, M.; Cozens, B.; Harper, A.; Hetherington, C. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87, 493-506.
25. DiFiglia, M. Huntingtin fragments that aggregate go their separate ways. Mol. Cell 2002, 10, 224-225.
26. Bates, G. P.; Hockly, E. Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials? Curr. Opin. Neurol. 2003, 16, 465-470.
27. Petersen, A.; Gil, J.; Maat-Schieman, M. L.; Bjorkqvist, M.; Tanila, H.; Araujo, I. M. et al. Orexin loss in Huntington's disease. Hum. Mol. Genet. 2005, 14, 39-47.
28. Strand, A. D.; Aragaki, A. K.; Shaw, D.; Bird, T.; Holton, J.; Turner, C. et al. Gene expression in Huntington's disease skeletal muscle: a potential biomarker. Hum. Mol. Genet. 2005, 14, 1863-1876.
29. Carter, R. J.; Lione, L. A.; Humby, T.; Mangiarini, L.; Mahal, A.; Bates, G. P. et al. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci. 1999, 19, 3248-3257.
30. Hockly, E.; Woodman, B.; Mahal, A.; Lewis, C. M.; Bates, G. Standardization and statistical approaches to therapeutic trials in the R6/2 mouse. Brain Res. Bull. 2003, 61, 469-479.
31. Davies, S. W.; Turmaine, M.; Cozens, B. A.; DiFiglia, M.; Sharp, A. H.; Ross, C. A. et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997, 90, 537-548.
32. Li, H.; Li, S. H.; Cheng, A. L.; Mangiarini, L.; Bates, G. P.; Li, X. J. Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Hum. Mol. Genet. 1999, 8, 1227-1236.
33. Luthi-Carter, R.; Strand, A.; Peters, N. L.; Solano, S. M.; Hollingsworth, Z. R.; Menon, A. S. et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease [In Process Citation]. Hum. Mol. Genet. 2000, 9, 1259-1271.
34. Luthi-Carter, R.; Hanson, S. A.; Strand, A. D.; Bergstrom, D. A.; Chun, W.; Peters, N. L. et al. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum. Mol. Genet. 2002, 11, 1911-1926.
35. Luthi-Carter, R.; Strand, A. D.; Hanson, S. A.; Kooperberg, C.; Schilling, G.; La Spada, A. R. et al. Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum. Mol. Genet. 2002, 11, 1927-1937.
36. Perluigi, M.; Poon, H. F.; Maragos, W.; Pierce, W. M.; Klein, J. B.; Calabrese, V. et al. Proteomic analysis of protein expression and oxidative modification in R6/2 transgenic mice - A model of Huntington's disease. Mol. Cell. Proteomics 2005, in press.
37. Zabel, C.; Chamrad, D. C.; Priller, J.; Woodman, B.; Meyer, H. E.; Bates, G. P. et al. Alterations in the mouse and human proteome caused by Huntington's disease. Mol. Cell. Proteomics 2002, 1, 366-375.
38. Mangiarini, L.; Sathasivam, K.; Mahal, A.; Mott, R.; Seller, M.; Bates, G. P. Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation. Nat. Genet. 1997, 15, 197-200.
39. Foxall, P. J.; Nicholson, J. K. Nuclear magnetic resonance spectroscopy: a noninvasive probe of kidney metabolism and function. Exp. Nephrol. 1998, 6, 409-414.
40. Garrod, S.; Humpfer, E.; Spraul, M.; Connor, S. C.; Polley, S.; Connelly, J. et al. High-resolution magic angle spinning 1H NMR spectroscopic studies on intact rat renal cortex and medulla. Magn. Reson. Med. 1999, 41, 1108-1118.
41. Wold, S.; Johannsson, E.; Cocchi, M. 3D-QSAR in Drug Design, Theory, Methods, and Applications, 2002.
42. Hoskuldsson, A. Prediction Methods in Science and Technology, Thor Publishing: Copenhagen, 1996.
43. Wold, S.; Albano, C.; Dunn, W. J.; Edlund, U.; Esbensen, K.; Geladi, P. et al. Multivariate Data Analysis in Chemistry, D. Reidel Publishing Company: Dordrecht, 1984.
44. Cloarec, O.; Dumas, M. E.; Trygg, J.; Craig, A.; Barton, R. H.; Lindon, J. C. et al. Evaluation of the orthogonal projection on latent structure model limitations caused by chemical shift variability and improved visualization of biomarker changes in 1H NMR spectroscopic metabonomic studies. Anal. Chem. 2005, 77, 517-526.
45. Jenkins, B. G.; Klivenyi, P.; Kustermann, E.; Andreassen, O. A.; Ferrante, R. J.; Rosen, B. R. et al. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. J. Neurochem. 2000, 74, 2108-2119.
46. Reynolds, N. C., Jr.; Prost, R. W.; Mark, L. P. Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington's disease. Brain Res. 2005, 1031, 82-89.
47. Jenkins, B. G.; Rosas, H. D.; Chen, Y. C.; Makabe, T.; Myers, R.; MacDonald, M. et al. 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology 1998, 50, 1357-1365.
48. Jenkins, B. G.; Koroshetz, W. J.; Beal, M. F.; Rosen, B. R. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology 1993, 43, 2689-2695.
49. Nitsch, R. M.; Blusztajn, J. K.; Pittas, A. G.; Slack, B. E.; Growdon, J. H.; Wurtman, R. J. Evidence for a membrane defect in Alzheimer disease brain. Proc. Natl Acad. Sci. U.S.A. 1992, 89, 1671-1675.
50. Boulanger, Y.; Labelle, M.; Khiat, A. Role of phospholipase A(2) on the variations of the choline signal intensity observed by 1H magnetic resonance spectroscopy in brain diseases. Brain Res. Brain Res. Rev. 2000, 33, 380-389.
51. Reynolds, G. P.; Dalton, C. F.; Tillery, C. L.; Mangiarini, L.; Davies, S. W.; Bates, G. P. Brain neurotransmitter deficits in mice transgenic for the Huntington's disease mutation. J. Neurochem. 1999, 72, 1773-1776.
52. Carter, C. J. Increased alanine aminotransferase activity in the Huntington's disease putamen. J. Neurol. Sci. 1984, 66, 27-32.
53. Nadeau, K. J.; Klingensmith, G.; Zeitler, P. Type 2 Diabetes in Children is Frequently Associated with Elevated Alanine Aminotransferase. J. Pediatr. Gastroenterol. Nutr. 2005, 41, 94-98.
54. Hussy, N.; Deleuze, C.; Desarmenien, M. G.; Moos, F. C. Osmotic regulation of neuronal activity: a new role for taurine and glial cells in a hypothalamic neuroendocrine structure. Prog. Neurobiol. 2000, 62, 113-134.
55. Viola, A.; Nicoli, F.; Denis, B.; Confort-Gouny, S.; Le Fur, Y.; Ranjeva, J. P. et al. High cerebral scyllo-inositol: a new marker of brain metabolism disturbances induced by chronic alcoholism. Magma 2004, 17, 47-61.
56. Turmaine, M.; Raza, A.; Mahal, A.; Mangiarini, L.; Bates, G. P.; Davies, S. W. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc. Natl Acad. Sci. U.S.A. 2000, 97, 8093-8097.
57. Hoang, T. Q.; Bluml, S.; Dubowitz, D. J.; Moats, R.; Kopyov, O.; Jacques, D. et al. Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's diseases. Neurology 1998, 50, 1033-1040.
58. Patel, T. B.; Clark, J. B. Synthesis of N-acetyl-L-aspartate by rat brain mitochondria and its involvement in mitochondrial/cytosolic carbon transport. Biochem. J. 1979, 184, 539-546.
59. Bates, T. E.; Strangward, M.; Keelan, J.; Davey, G. P.; Munro, P. M.; Clark, J. B. Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. Neuroreport. 1996, 7, 1397-1400.
60. Tabrizi, S. J.; Workman, J.; Hart, P. E.; Mangiarini, L.; Mahal, A.; Bates, G. et al. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann. Neurol. 2000, 47, 80-86.
61. Tsang, T. M.; Griffin, J. L.; Haselden, J.; Fish, C.; Holmes, E. Metabolic characterization of distinct neuroanatomical regions in rats by magic angle spinning 1H nuclear magnetic resonance spectroscopy. Magn. Reson. Med. 2005, 53, 1018-1024.
62. Taylor-Robinson, S. D.; Weeks, R. A.; Bryant, D. J.; Sargentoni, J.; Marcus, C. D.; Harding, A. E. et al. Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory. Mov. Disord. 1996, 11, 167-173.
63. Magistretti, P. J.; Pellerin, L.; Rothman, D. L.; Shulman, R. G. Energy on demand. Science 1999, 283, 496-497.
64. Hockly, E.; Tse, J.; Barker, A. L.; Moolman, D. L.; Beunard, J.-L.; Revington, A. P. et al. Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease. Neurobiol. Dis. 2005, in press.
65. Lodi, R.; Schapira, A. H.; Manners, D.; Styles, P.; Wood, N. W.; Taylor, D. J. et al. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann. Neurol. 2000, 48, 72-76.
66. Bjorkqvist, M.; Fex, M.; Renstrom, E.; Wierup, N.; Petersen, A.; Gil, J. et al. The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient beta-cell mass and exocytosis. Hum. Mol. Genet. 2005, 14, 565-574.
67. Podolsky, S.; Leopold, N. A.; Sax, D. S. Increased frequency of diabetes mellitus in patients with Huntington's chorea. Lancet 1972, 1, 1356-1358.
68. Farrer, L. A. Diabetes mellitus in Huntington disease. Clin. Genet. 1985, 27, 62-67.
69. Wang, X.; Ikeguchi, Y.; McCloskey, D. E.; Nelson, P.; Pegg, A. E. Spermine synthesis is required for normal viability, growth, and fertility in the mouse. J. Biol. Chem. 2004, 279, 51370-51375.
70. Markianos, M.; Panas, M.; Kalfakis, N.; Vassilopoulos, D. Plasma testosterone in male patients with Huntington's disease: relations to severity of illness and dementia. Ann. Neurol. 2005, 57, 520-525.
71. Papalexi, E.; Persson, A.; Bjorkqvist, M.; Petersen, A.; Woodman, B.; Bates, G. P. et al. Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease. Eur. J. Neurosci. 2005, In press.